对诊断PADAM的游离睾酮指数的评估

目的 评价诊断中老年男子部分雄激素缺乏综合征（PADAM）的游离睾酮指数（FTI）.方法 对129例45岁以上健康男性的FTI进行年龄相关分析.以推算的游离睾酮（CFT）值为依据,对FTI进行有效性检验.结果 男子在中老年期FTI与增龄呈明显的负相关.FTI敏感性97.78%,特异性58.33%.结论 计算简单的FTI可用于PADAM病人的筛选和随访,尤其对70岁以上男子是血清FT较为有效的参数.     

Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction

Vascular 18F-FDG uptake marker represents inflammation in atherosclerotic lesions, but whether inflammation can be reversed by risk-modifying interventions has not, to our knowledge, been demonstrated. In this study, we evaluated the change of vascular 18F-FDG uptake in response to lifestyle intervention on serial PET/CT scans and further assessed how the findings relate to atherogenic risk reduction. METHODS: A total of 60 healthy adults underwent 18F-FDG PET/CT scans and atherogenic risk-factor assessment at baseline and again after 17.1 +/- 8.3 mo of practicing lifestyle modification. The PET/CT images were evaluated for the presence of vascular 18F-FDG lesions, and vessel-to-blood-pool 18F-FDG ratios were measured. Indices from summed ratios of positive lesions were compared and correlated to atherogenic risk factors. RESULTS: At follow-up, significant reductions in diastolic blood pressure (P < 0.05), total cholesterol (P < 0.05), and low-density lipoprotein level (P < 0.05) and an increase in high-density lipoprotein (HDL) level (P < 0.0001) were demonstrated. On the initial PET/CT scan, 50 of 60 subjects showed 1 or more 18F-FDG-positive lesions (5.9 +/- 5.0/subject), leading to a total of 352 vascular sites. On follow-up, 18F-FDG-positive lesions were significantly reduced to 2.1 +/- 2.2 sites per subject (P < 0.0001) and a total of 124 sites (64.8% reduction). Follow-up 18F-FDG-positive rates were significantly reduced for the aorta and iliac arteries. In addition, significant reductions in the whole-body 18F-FDG index from 1.39 +/- 1.23 to 0.53 +/- 0.59 (P < 0.0001) and carotid 18F-FDG index from 0.08 +/- 0.16 to 0.03 +/- 0.06 (P = 0.01) were shown. The whole-body 18F-FDG index correlated with total cholesterol (P < 0.05) and HDL level (P < 0.05), and the magnitude of reduction in the 18F-FDG index closely correlated to the amount of increase in plasma HDL level (P = 0.005). CONCLUSION: Our study demonstrated that vascular 18F-FDG uptake is reversed in response to atherogenic risk reduction by lifestyle intervention and that the magnitude of improvement correlates to increases in plasma HDL levels. Thus, serial 18F-FDG PET/CT may be useful for monitoring improvements in the inflammatory component of atherosclerotic lesions in response to risk modification.     

医学研究生临床技能培训与和谐医患关系构建的协调发展

临床技能培训与和谐医患关系构建是临床医学教育中两个不可分割的重要组成部分.促进临床技能培训与和谐医患关系的协调发展,达到完美和谐的统一,以提高医学研究生的培养质量.武汉大学人民医院采用具有特色的新型培养方式,加强研究生法律意识、医德教育,注重换位思考,提高专业技能,保持心理健康,改进医患沟通技巧,在研究生教育工作中取得了良好的效果.     

α-平滑肌肌动蛋白和β-肌动蛋白在瘢痕组织中的表达

目的 探讨α-平滑肌肌动蛋白(α-SMA)和β-肌动蛋白(β-actin)对增生性瘢痕形成的可能作用。方法 采用荧光定量PCR法检测10例增生性瘢痕和10例正常皮肤组织中α-SMA和β-actin的表达水平。结果 增生性瘢痕组织中α-SMA和β-actin表达水平均高于正常皮肤组织,差异有统计学意义(P<0.01)。结论 α-SMA和β-actin在瘢痕增生中起重要作用;由于β-actin在瘢痕组织和正常皮肤中的不恒定性,建议在瘢痕的mRNA定量研究中不作为内参照物。     

颈性眩晕的分型治疗及疗效分析

目的 将颈性眩晕分为上、下颈性眩晕，采取不同治疗方法并与常规治疗方法的疗效比较，以寻求更好的治疗方法。方法 将135例颈性眩晕随机分为试验组和对照组，对其治愈率及治疗时间进行统计学分析。结果 试验组的治愈率高于对照组，而试验组的治疗时间短于对照组，均有统计学意义。结论 对颈性眩晕进行分型并采用不同的治疗方法能提高治愈率，缩短治疗时间。     

瘢痕成纤维细胞中TGF-β受体与整合素相互作用的实验研究

目的:了解TGF-β受体和整合素在瘢痕增生和挛缩过程中的作用.方法:通过荧光定量PCR法(FQ-PCR)测定经TGF-β受体、整合素和粘着斑激酶(FAK)抗体阻断后培养的瘢痕成纤维细胞TGF-β受体以及整合素表达量的变化.结果:经不同抗体阻断后培养的瘢痕成纤维细胞其TGF-β RI和整合素β 1的基因拷贝数均较阴性对照组有不同程度的下降(P＜0.05).结论:TGF-β受体和整合素介导的信号传导途径间可能存在着正反馈的效应,共同促进瘢痕的增生和挛缩.FAK是两条信号传导途径的交汇点和作用的中心环节.     

关于我国体外诊断试剂监督管理改革的建议

本文综述了美国、欧盟、日本、中国目前对体外诊断产品（试剂）监督管理的现状以及我国存在的问题。并根据我国具体情况提出了对体外诊断试剂监督管理的改革建议。     

泰素蒂加顺铂治疗进展期NSCLC的临床研究

目的观察泰素蒂加顺铂方案治疗进展期非小细胞肺癌的临床疗效、毒副作用。方法收集可评价疗效的进展期非小细胞肺癌50例,以泰素蒂加顺铂方案进行化疗,泰素蒂75 mg/m2静脉滴注,第1天;顺铂25 mg/m2～30 mg/m2静脉滴注,第2天～第5天,每3周为一个周期,2～3周期后评价疗效和毒副反应并随访。结果50例患者中,总有效率为50.0 %,其中初治病例为53.1 %,复治病例为44.4 %,初复治病例间差异无显著性(P >0.05)。中位缓解期为5个月。中位生存期为9.5个月,1年生存率为61.0 %。毒副反应主要为骨髓抑制,白细胞下降达Ⅲ度、Ⅳ度者52.0 %,血小板下降达Ⅲ度、Ⅳ度者为14.0 %。血红蛋白下降不严重。其他毒副反应还有脱发、过敏反应、水钠潴留、静脉炎、末梢神经炎、口腔炎、腹泻等,但发生率均较低。结论泰素蒂加顺铂方案治疗进展期非小细胞肺癌,特别是复发病例,临床疗效比较满意,毒副反应能够耐受。辅以G蛳CSF可防治重度的骨髓抑制,有较好的临床应用价值。